Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301117 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
A Phase 1 study of Advanced Solid Tumors, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 14
- Study locations
NCT02301117 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Taiho Oncology. The registered enrollment target is 43 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT02301117, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 14
- Study locations
Study Summary
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
Conditions Studied
Interventions
- DRUG TAS-102
Study Locations (14)
Other
- Brno Clinical Site - Brno
- Praha Clinical Site - Prague
- Belgrade Clinical Site - Belgrade
- Sremska Kamenica Clinical Site - Kamenitz
California
- Duarte Clinical Site - Duarte
- Santa Monica Clinical Site - Santa Monica
Ohio
- Cleveland Clinical Site - Cleveland
- Cleveland Clinical Site - Cleveland
Arizona
- Phoenix Clinical Site - Phoenix
Florida
- Gainesville Clinical Site - Gainesville
Maryland
- Baltimore Clinical Site - Baltimore
Massachusetts
- Boston Clinical Site - Boston
Pennsylvania
- Pittsburgh Clinical Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301117
The ClinicalTrials.gov registry entry for NCT02301117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower). The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TAS-102 is the first listed.
NCT02301117 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02301117 about?
NCT02301117 is a clinical study titled "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment". Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
What is the current status of trial NCT02301117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-01. Estimated completion is 2019-06-19.
What conditions does trial NCT02301117 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02301117?
The interventions under investigation include: TAS-102 (DRUG).
Who is sponsoring clinical trial NCT02301117?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301117 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.